文献速递中医内科中药与中成药合理使用

麝香保心丸治疗非ST段抬高型急性冠脉综合征的系统评价

A Chinese patent medicine, Shexiang Baoxin Pill, for Non-ST-elevation acute coronary syndromes: A systematic review.
PubMed 文献 · J Ethnopharmacol · 2016-11-12

结果显示联合治疗可能降低心血管事件和住院风险、改善心绞痛症状和心电图表现,不良事件总发生率未升高,但纳入试验偏倚风险高、质量差,尚不足以支持常规使用结论。

要点

  • 麝香保心丸联合常规治疗可能降低NSTE-ACS患者心血管事件风险(RR=0.36)。
  • 联合治疗可能减少住院(RR=0.38)并改善心绞痛症状(RR=1.19)。
  • 不良事件总发生率未升高,但证据质量低,需高质量试验验证。

核心结论

  • 麝香保心丸联合常规治疗可能对NSTE-ACS长期结局有益且未增加严重不良事件。
  • 因纳入试验偏倚风险高、质量差,目前无充分证据支持其常规使用。

研究设计与样本

  • 系统评价与荟萃分析,遵循PRISMA声明。

主要发现

  • 心血管事件风险降低(RR=0.36,95% CI 0.26-0.49,P<0.00001)。
  • 住院风险降低(RR=0.38,95% CI 0.21-0.67,P=0.0009)。
  • 心绞痛症状改善(RR=1.19,95% CI 1.13-1.26,P<0.00001)。
  • 心电图测量改善(RR=1.25,95% CI 1.13-1.39,P<0.00001)。
  • 不良事件总发生率未升高(P=0.43)。

关键数值与推荐

  • 主要临床结局为心血管事件风险。
  • 次要结局包括住院、心绞痛症状、心电图测量和不良事件。

临床怎么用

  • 在常规治疗基础上可考虑联合麝香保心丸用于NSTE-ACS长期管理。
  • 需结合试验质量低、偏倚风险高的局限,谨慎解释获益证据。

局限性

  • 纳入试验总体偏倚风险高、质量差。
  • 尚无足够证据得出常规使用结论,需大样本方法学严谨的试验进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Shexiang Baoxin Pill (SXBXP) is a well-known Chinese patent medicine, widely used for Non-ST-elevation acute coronary syndromes (NSTE-ACS). It is composed of seven materia medicas or extracts (Moschus, Radix Ginseng, Calculus Bovis, Cortex Cinnamomi, Styrax, Venenum Bufonis and Borneolum Syntheticum). AIM OF THE STUDY: This study is aimed to systematically review the relevant randomised controlled trials (RCTs) to determine the efficacy and safety of SXBXP for long-term management of NSTE-ACS. MATERIALS AND METHODS: A systematic review and meta-analysis were carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. All randomised controlled trials (RCTs) comparing long-term Shexiang Baoxin Pill with conventional treatment, with outcome measures relating to efficacy and safety were selected. Primary clinical outcome was the risk of cardiovascular events, secondary outcomes were hospitalizations, angina symptoms, electrocardiogram (ECG) measurements, and adverse events. RESULTS: Eleven RCTs recruiting 1389 patients were included, the overall risk of bias of the included trials is high and the quality poor. Compared with conventional treatment alone, long-term Shexiang Baoxin Pill plus conventional treatment might be more effective in lowering the risk of cardiovascular events (RR=0.36, 95% CI 0.26-0.49, <0.00001), hospitalizations (RR=0.38, 95% CI 0.21-0.67, P=0.0009), and improving angina symptoms (RR=1.19, 95% CI 1.13-1.26, P<0.00001), ECG measurements (RR=1.25, 95% CI 1.13-1.39, P<0.00001). Overall rate of adverse events was not elevated (P=0.43). CONCLUSIONS: From the available evidence, SXBXP added to conventional treatment may have beneficial effects on the long-term outcomes of NSTE-ACS, without serious adverse events. However, given the high risk of bias and low quality of the included trials, currently, there is no adequate evidence to draw any conclusions about its routine use. Large, methodologically-sound trials are needed to further assess its effects.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Zhou Z, Shen W, Yu L, et al. A Chinese patent medicine, Shexiang Baoxin Pill, for Non-ST-elevation acute coronary syndromes: A systematic review. J Ethnopharmacol. 2016. PMID: 27847338. doi:10.1016/j.jep.2016.11.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。